Current controversies in deep vein thrombosis prophylaxis after orthopaedic surgery

Current Opinion in Pulmonary Medicine

Volumn 8, Issue 5, 2002, Pages 394-397

  Dahl, Ola E ^a   Bergqvist, David ^b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTEIN C; WARFARIN;

ANTICOAGULATION; BLEEDING; CAUDA EQUINA SYNDROME; CLINICAL RESEARCH; COST BENEFIT ANALYSIS; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG EFFICACY; HEALTH CARE COST; HEALTH ECONOMICS; HIGH RISK POPULATION; HUMAN; MEASUREMENT; MORBIDITY; ORTHOPEDIC SURGERY; PROPHYLAXIS; REVIEW; SURGICAL MORTALITY; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT;

EID: 0036325729     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200209000-00009     Document Type: Review

References (37)

1. Fibrin formation and platelet aggregation in patients with acute myocardial infarction: Effects of intravenous and subcutaneous low dose heparin
2. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina
3. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes
4. Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery
5. Studies on coagulation, fibrinolysis, kallikrein-kinin and complement activation in systemic and pulmonary circulation during hip arthroplasty with acrylic cement
6. Sequential intrapulmonary and systemic activation of coagulation and fibrinolysis during and after hip replacement
7. The role of bone traumatization and methyl-methacrylate monomer cytotoxicity in the initiation on proximal deep vein thrombosis during cemented hip replacement in pigs
8. The John Charnley Award. Thrombogenesis during total hip arthroplasty
9. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty
10. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: A double-blind, randomized comparison
11. A dose-response study of the Factor VIIa/Tissue factor inhibitor r NAPc2 in the prevention of postoperative venous thrombosis in patients undergoing total knee arthroplasty
12. The influence of anticoagulation therapy on deep vein thrombosis rates four weeks after total hip replacement
13. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomized comparison enoxaparin versus placebo
14. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement
15. Prolonged thromboprophylaxis following hip replacement surgery
16. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty - The Danish prolonged prophylaxis study
17. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients after elective hip arthroplasty: A systematic review
18. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement
19. Total hip replacement, lower limb blood flow and venous thrombogenesis
20. Venous hemodynamics in both legs after total knee replacement
21. Late occurring deep vein thrombosis in operated patients
22. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty
23. Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty - A meta-analysis
24. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: A meta-analysis of the randomized trials
25. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients after elective hip arthroplasty: A systematic review
26. Mortality after total hip replacement. 0-10-Year follow-up of 39,543 patients in the Norwegian Arthroplasty Register
27. The post-mortem incidence of pulmonary emobolism in a hospital population
28. Deep vein thrombosis and pulmonary embolism. An autopsy study with multiple regression analysis of possible risk factors
29. Autopsy proven embolism in hospital patients: Are we detecting enough deep vein thrombosis?
30. Dalteparin (Fragmin) for the prevention of early mortality after orthopaedic surgery
31. Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin
32. Cost-effectiveness of prolonged out-of-hospital prophylaxis with low-molecular-weight heparin following total hip replacement
33. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery
34. A randomized, controlled study of the oral direct thrombin inhibitor, H376/95, and its active form, melagatran, compared with dalteparin as thromboprophylaxis after total hip or total knee replacement: Methro II